Introduction As part of our tertiary multi-disciplinary complex breathlessness service we run a weekly 'one-stop assessment day' for new referrals. Referral requests include assessment of refractory breathlessness felt due to inducible laryngeal obstruction (ILO) and/or dysfunctional breathing. Patients undergo clinical history and evaluation, spirometry, fractional exhaled nitric oxide (FENO), blood testing and laryngoscopy (with challenge if appropriate). Aims To evaluate initial clinical plans of those attending onestop assessment days and understand the prevalence and type of medical comorbidities. Methods Patient demographics and clinical data were retrospectively collated from clinical records of individuals who attended for assessment between November 2016 and June 2017. Results Full assessments were available for 79 patients [72% female; mean (SD) age 45.6 (13.6) years; FEV 1 (n=40) 2.6 (0.7) L; FVC (n=40) 3.3 (0.9) L; FENO (n=33) 39.0 (41.2) ppb; blood eosinophils (n=68) median (range) 0.2 (0.1-2.9) x10 9 cells/ml]. Fifty two percent had endoscopically confirmed inspiratory ILO, and of these 15% had an associated dysfunctional breathing pattern. Initial clinic plans included instigation of medical treatment (n=12), further investigations of untreated co-morbidities (n=33), speech and language therapy treatment (n=30), physiotherapy assessment and treatment (n=9) and onward referral to non-respiratory specialists (n=5). Of those requiring further investigation 73% were asthma related and 21% were for reflux. Medical treatments instigated were mainly related to asthma or bronchiectasis (92%). Secondary analysis of those needing further investigation or medical treatment revealed 39% had inspiratory laryngeal obstruction, 13% had exaggerated expiratory closure, and 23% had noted laryngeal hypersensitivity alone. Conclusion There is a significant proportion of individuals who have untreated or under investigated co-morbidity (predominantly asthma) when referred for specialist complex breathlessness assessment. Those with untreated disease demonstrated abnormal responses in the upper airway and further support the relationship between ILO and asthma. Optimised medical intervention is important to ensure any aggravants of secondary diagnoses (e.g., ILO) are addressed adequately and their impact is minimised.
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CAN MASKS PROTECT YOU FROM AIR POLLUTION?
NM Liu, T Wan, EC Russell-Jones, J Grigg. Queen Mary University of London, London, UK 10. 1136/thoraxjnl-2017-210983.288 Introduction Inhalation of diesel soot (black carbon) is associated with respiratory morbidity and mortality. Numerous facemasks that claim to reduce inhaled dose are available commercially, often aimed at the cycling community. To date it remains unclear whether these actually reduce exposure. In this study we sought to assess the effectiveness of some of masks available in the UK. Methods We chose to assess 5 facemasks; i) Totobobo, ii) FFP3 industrial, iii) surgical, iv) Respro City Anti-Pollution, and v) Dettol Protect+. Masks was placed using an air tight seal at one end of a spacer chamber (Aerochamber). Researchers breathed through the spacer, and air within the spacer chamber sampled by an aethalometer (MicroAeth AE51) every 30 s. For each 30 s period, spacer black carbon (ng/m 3 ) was compared with ambient black carbon. Each mask was tested for at least 15 min on the pavement of busy roads in Marylebone and Whitechapel. Data are expressed as; i) mean of difference (±SEM) between ambient and spacer air black carbon and ii) as percentage reduction of mean black carbon. Data are compared by paired T-test. Results Totobobo mask was the most effective with a mean difference of À2022 ng/m 3 (±175 ng/m 3 , p<0.0001; 71% reduction, figure 1) 
